Axsome Therapeutics Inc (AXSM)

Axsome Therapeutics (AXSM) Financial Statements


Axsome Therapeutics Financial Overview

Axsome Therapeutics's market cap is currently ―. The company's EPS TTM is $-4.578; its P/E ratio is -13.43; Axsome Therapeutics is scheduled to report earnings on May 10, 2023, and the estimated EPS forecast is $-1.30. See an overview of income statement, balance sheet, and cash flow financials.
Dec 22Sep 22Jun 22Mar 22Dec 21
Income Statement-
Total Revenue$ 24.37M$ 16.85M$ 8.82M$ 0.00$ 0.00
Gross Profit$ 22.08M$ 14.92M$ 7.84M--
EBIT$ -59.92M$ -42.41M$ -39.18M$ -38.29M$ -32.61M
EBITDA$ -57.90M$ -40.45M$ -37.91M$ -37.98M$ -32.30M
Net Income Common Stockholders$ -61.24M$ -44.82M$ -41.44M$ -39.63M$ -33.98M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 200.84M$ 227.52M$ 73.39M$ 84.71M$ 86.47M
Total Assets$ 331.48M$ 338.96M$ 180.56M$ 88.56M$ 87.79M
Total Debt$ 94.68M$ 94.33M$ 94.17M$ 50.28M$ 49.71M
Net Debt$ -106.16M$ -133.19M$ 20.77M$ -34.43M$ -36.76M
Total Liabilities$ 221.92M$ 181.60M$ 165.36M$ 73.86M$ 72.15M
Stockholders Equity$ 109.56M$ 157.36M$ 15.20M$ 14.70M$ 15.63M
Cash Flow-
Free Cash Flow$ -27.74M$ -22.82M$ -33.78M$ -32.87M$ -28.84M
Operating Cash Flow$ -27.56M$ -22.76M$ -33.54M$ -32.65M$ -28.84M
Investing Cash Flow$ -180.86K$ -66.06K$ -53.24M$ -213.74K$ 0.00
Financing Cash Flow$ 1.07M$ 176.95M$ 75.46M$ 31.10M$ 690.48K
Currency in USD

Axsome Therapeutics Earnings and Revenue History

Axsome Therapeutics Debt to Assets

Axsome Therapeutics Cash Flow

Axsome Therapeutics Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis